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Abstract: Mucorales are fungi with increasing importance in the clinics. Infections take a rapidly
progressive course resulting in high mortality rates. The ergosterol biosynthesis pathway and
sterol composition are of interest, since they are targeted by currently applied antifungal drugs.
Nevertheless, Mucorales often exhibit resistance to these drugs, resulting in therapeutic failure.
Here, sterol patterns of six clinically relevant Mucorales (Lichtheimia corymbifera, Lichtheimia ramosa,
Mucor circinelloides, Rhizomucor pusillus, Rhizopus arrhizus, and Rhizopus microsporus) were analysed
in a targeted metabolomics fashion after derivatization by gas chromatography-mass spectrometry.
Additionally, the effect of posaconazole (POS) treatment on the sterol pattern of R. arrhizus was
evaluated. Overall, fifteen different sterols were detected with species dependent variations in the
total and relative sterol amount. Sterol analysis from R. arrhizus hyphae confronted with sublethal
concentrations of posaconazole revealed the accumulation of 14-methylergosta-8,24-diene-3,6-diol,
which is a toxic sterol that was previously only detected in yeasts. Sterol content and composition
were further compared to the well-characterized pathogenic mold Aspergillus fumigatus. This work
contributes to a better understanding of the ergosterol biosynthesis pathway of Mucorales, which is
essential to improve antifungal efficacy, the identification of targets for novel drug design, and to
investigate the combinatorial effects of drugs targeting this pathway.
Keywords: Mucorales; Rhizopus arrhizus; sterol pattern; antifungal effectivity; gas chromatography-
mass spectrometry (GC-MS); posaconazole
1. Introduction
The order Mucorales represent the most prominent order of zygospore-forming fungi, which was
formerly placed in the phylum Zygomycota and was referred to as Zygomycetes. Over the
years, this phylum has undergone constant taxonomic rearrangements. Now, the Mucorales,
or mucormycetes, are placed in the phylum Glomeromycota and subphylum Mucormycotina [1–3].
Mucorales are mainly saprophytes commonly found in soil and decomposing material. Members of this
group play various important roles for human life—e.g., Mucor spp., are of biotechnological importance
due to their high growth rates and their great potential in the production of secondary metabolites [4].
Other Mucorales, such as Rhizopus spp., have been used for food fermentation in Asia for centuries [5].
Contrary to these positive effects of mucoralean fungi on human life, they also cause a wide range
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of diseases to plants, animals, and human beings. In the last ten years, the number of mucormycosis
cases (also known as zygomycosis) [3,6] has increased significantly in the clinics. Mucorales that
were isolated in high abundance from patient material belong to the following genera: Rhizopus,
Lichtheimia (formerly Absidia), Mucor, Rhizomucor, and Cunninghamella. Worldwide, Rhizopus arrhizus
is the most common species that was isolated from clinical specimen. The clinical presentation of
mucormycosis varies, with mostly rhinocerebral, pulmonary and gastrointestinal manifestations.
Primarily, immunocompromised patients are at risk to develop mucormycosis, but some forms, such as
cutaneous mucormycosis, have also been seen in otherwise healthy persons [1,7]. The aggressive
course of the disease, delayed diagnosis, and poor treatment options result in unacceptably high
mortality rates (40–70%), even with antifungal therapy. Often, mucormycosis is seen as so called
breakthrough infection when voriconazole is applied as prophylactic treatment regime [6]. Antifungal
drugs currently licensed for treatment of mucormycosis are the polyene antifungal amphotericin B
(AMB), preferably the liposomal formulation as first line treatment, and the triazole posaconazole as
salvage treatment. In 2015, another azole, isavuconazole (ISA), was approved by the Food and Drug
Administration (FDA) as a stand-alone treatment for mucormycosis [1,8–13]. AMB forms 1:1 adducts
with fungal ergosterol and induces an accumulation of reactive oxygen species in the cytoplasm [14,15].
Azoles conduct their antifungal activity by inhibiting the enzyme sterol C14-demethylase (named
ERG11 in yeasts, and CYP51 in Aspergillus spp., Figure 1, enzyme A) [16,17]. POS is also very active
against Aspergillus isolates and used in the therapy of invasive aspergillosis. In contrast, another
second-generation triazole, voriconazole (VRC), was shown to have no in vitro nor in vivo activity
against Mucormycetes [13,15,18–20]. The limited arsenal of highly active anti-mucoralean drugs,
plus the occurrence of AMB and azole resistant strains highlight the importance of illuminating the
mode of action of antifungal drugs on, and resistance mechanisms in this group of fungi [13,15].
As the target of the currently used antifungal drugs against Mucorales is ergosterol or its biosynthesis,
respectively, it is of great importance to understand the biosynthetic pathway and decipher the
differences to other human pathogenic fungi.
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For two major human pathogenic fungi, the yeast Candida albicans, and the mold Aspergillus 
fumigatus, differences in the ergosterol biosynthesis pathways have already been elucidated. In 
Candida spp., and this is similar to baker´s yeast S. cerevisiae (Figure 1, upper panel), lanosterol is the 
preferred substrate for the sterol C14‐demethylase (Figure 1, enzyme A), which converts lanosterol 
into 4,4‐dimethylcholesta‐8,14,24‐trien‐3β‐ol [21–25]. In molds, e.g., Aspergillus fumigatus, the 
preferred ergosterol biosynthesis route from lanosterol starts with a methylation at C‐24 by sterol 
C24‐methyltransferase (enzyme B) in order to give eburicol, and is then followed by a demethylation 
at C‐14 by sterol C14‐demethylase to give 4,4‐dimethylergosta‐8,14,24(28)‐trien‐3β‐ol [24–26] (Figure 
1, lower panel). 
In the presence of azoles, the accumulation of physiological substrates for sterol C14‐
demethylase and a depletion of ergosterol are observed in both yeasts and molds [16,25,27–30]. The 
accumulation of C14‐methylated sterols (e.g., lanosterol (10) and eburicol (13)) and lower levels of 
ergosterol as the predominant native sterol in fungi or changes in the relative sterol composition 
Figure 1. Preferred ergosterol biosynthesis pathways in yeasts (S. cerevisiae) and molds (A. fumigatus)
starting from lanosterol. Enzymes: (A) sterol C14-demethylase, (B) sterol C24-methyltransferase.
For two major human pathogenic fungi, the yeast Candida albicans, and the mold
Aspergillus fumigatus, differences in the ergosterol biosynthesis pathways have already been elucidated.
In Candida spp., and this is similar to baker´s yeast S. cerevisiae (Figure 1, upper panel), lanosterol
is the preferred substrate for the sterol C14-demethylase (Figure 1, enzyme A), which converts
lanosterol into 4,4-dimethylcholesta-8,14,24-trien-3β-ol [21–25]. In molds, e.g., Aspergillus fumigatus,
the preferred ergosterol biosynthesis route from lanosterol starts with a methylation at C-24 by sterol
C24-methyltransferase (enzyme B) in order to give eburicol, and is then followed by a demethylation
at C-14 by sterol C14-demethylase to give 4,4-dimethylergosta-8,14,24(28)-trien-3β-ol [24–26] (Figure 1,
lower panel).
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In the presence of azoles, the accumulation of physiological substrates for sterol C14-demethylase
and a depletion of ergosterol are observed in both yeasts and molds [16,25,27–30]. The accumulation
of C14-methylated sterols (e.g., lanosterol (10) and eburicol (13)) and lower levels of ergosterol as the
predominant native sterol in fungi or changes in the relative sterol composition results in alterations of
the plasma membrane that impact its function and the activity of membrane-bound enzymes [31–33].
So far, very little is known about the ergosterol biosynthesis pathway, the sterol content, and the
composition of clinically relevant Mucorales, and most studies were carried out with one species or
one strain only, which makes the comparison in-between the group of Mucorales difficult [26,34–39].
Therefore, a full understanding of the ergosterol biosynthesis pathway and the sterol pattern of this
group of pathogenic fungi is essential to determine the efficacy of antifungal therapy, to identify
targets for novel drug design, and to investigate the combinatorial effects of drugs targeting the
ergosterol biosynthesis pathway. Here, the sterol pattern and sterol content of six clinically relevant
Mucorales (Rhizopus (R.) arrhizus, Rhizopus microsporus Lichtheimia (L.) corymbifera, Lichtheimia ramosa,
Mucor (M.) circinelloides, and Rhizomucor (Rh.) pusillus) were analysed in a targeted metabolomics
fashion by gas chromatography-mass spectrometry (GC-MS). In addition, sterols in hyphae of R. arrhizus
that was confronted with sub-lethal concentrations of posaconazole were analysed and compared
to untreated hyphae. R. arrhizus was chosen for this test because it represents the most abundant
Mucorales species from patient material worldwide. Furthermore, the obtained data were compared to
the well-studied ergosterol biosynthetic pathway of Aspergillus fumigatus [16,24,25,27,30,40–46].
2. Results and Discussion
2.1. Relative and Absolute Amounts of Sterol Intermediates in Mucorales
In total, 14 different sterols were detected (Table 1) in the six investigated Mucormycetes
(without azole treatment), which are discussed in the order of their retention time below (Figure 2,
blue chromatogram).
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Table 1. Sterol content and sterol composition of six different mucormycete species and A. fumigatus. Cultures were grown in RPMI1640 medium over night at 37 ◦C
before sterol extraction. The results are presented as the average of two independent experiments, comprising 6 technical replicates in total. Sterol composition is
given as the relative amount of the respective sterol (%, in bold letters) of all the sterols detected. Sterol content is expressed as µg sterol intermediate/mg biomass
(dry weight). Standard deviation is given in brackets. * n.d. = not detected, ** i.t. = in traces (< 0.04 µg/mg); major sterols are indicated in red.
Compound Relative [%] and Absolute [µg/mg] Amount of Sterols in Each Species
No. IUPACName
Common
Name L. corymbifera L. ramosa M. circinelloides Rh. pusillus R. arrhizus R. microsporus A. fumigatus
1 ergosta-5,8,22-trien-3β-ol Lichesterol
0.2
0.02 (± 0.00)
0.4
0.07 ± 0.02)
0.3
0.07 (± 0.00)
0.2
0.05 (± 0.00)
0.8
0.07 (± 0.01
0.9
0.13 (± 0.02
1.2
0.12 (± 0.03)
2 ergosta-5,7,22-trien-3β-ol Ergosterol
57.5
6.45 (± 0.66)
69.2
13.69 (± 3.76)
65.8
12.93 (± 0.37)
38.0
8.13 (± 0.33)
76.3
7.07 (± 0.04)
70.3
9.91 (± 1.85)
95.0
9.29 (± 2.28)
3 ergosta-7,22-dien-3β-ol
3.5
0.39 (± 0.04)
i.t. ** n.d. *
1.9
0.41 (± 0.02)
0.2
0.02 (± 0.01)
0.2
0.03 (± 0.02)
n.d.
4 ergosta-5,7,22,24(28)-tetraen-3β-ol
0.4
0.04 (± 0.00)
0.6
0.11 (± 0.00)
0.5
0.10 (± 0.01)
0.3
0.06 (± 0.00)
1.0
0.09± 0.02)
1.2
0.17 (± 0.03)
0.7
0.06 (± 0.01)
5 ergosta-7,22,24(28)-trien-3β-ol
0.2
0.02 (± 0.01)
0.2
0.04 (± 0.03)
0.2
0.04 (± 0.00)
0.2
0.03 (± 0.02)
0.2
0.03 ± 0.02)
0.2
0.03 (± 0.02)
0.2
0.02 (± 0.00)
6 ergosta-5,7,24(28)-trien-3β-ol n.d. *
7.4
1.50 (± 1.94)
10.4
2.05 (± 0.37)
n.d. **
2.6
0.24 ± 0.22)
3.3
0.46 (± 0.39)
0.6
0.06 (± 0.01)
7 ergosta-5,7-dien-3β-ol
28.5
3.19 (± 0.36)
12.3
2.48 (± 0.11)
10.6
2.07 (± 0.26)
37.2
9.96 (± 0.07)
10.6
0.98 (± 0.19)
12.9
1.82 (± 0.43)
0.3
0.03 (± 0.00)
8 ergosta-7,24(28)-dien-3β-ol Episterol
2.4
0.27 (± 0.04)
1.9
0.38 (± 0.13)
1.8
0.35 (± 0.01)
1.4
0.29 (± 0.01)
2.1
0.20 (± 0.13)
2.4
0.34 (± 0.19)
0.8
0.08 (± 0.01)
9 ergost-7-en-3β-ol
3.7
0.41 (± 0.02)
0.1
0.02 (± 0.03)
i.t. **
3.0
0.64 (± 0.02)
0.3
0.03 (± 0.02)
0.5
0.07 (± 0.03)
n.d. *
10 4,4,14-trimethylcholesta-8,24-dien-3β-ol Lanosterol
0.3
0.03 (± 0.00)
1.1
0.21 (± 0.24)
1.3
0.26 (± 0.04)
0.7
0.07 (± 0.03)
0.7
0.07 (± 0.03)
1.0
0.14 (± 0.05)
0.2
0.02 (± 0.00)
11 4,4-dimethylcholesta-8,24-dien-3β-ol T-MAS
0.2
0.04 (± 0.00)
0.6
0.12 (± 0.13)
0.7
0.15 (± 0.01)
0.6
0.13 (± 0.01)
0.2
0.02 (± 0.00)
0.2
0.03 (± 0.00)
0.4
0.04 (± 0.00)
12 4-methylergost-8-en-3β-ol
0.4
0.05 (± 0.00)
0.1
0.01 (± 0.02)
i.t. **
0.9
0.18 (± 0.00)
0.2
0.02 (± 0.02)
0.2
0.02 (± 0.02)
n.d. *
13 4,4,14-trimethylergosta-8,24(28)-dien-3β-ol Eburicol
2.0
0.22 (± 0.01)
5.3
1.07 (± 1.33)
7.2
1.41 (± 1.16)
15.4
3.29 (± 0.18)
3.7
0.34 (± 0.12)
5.5
0.77 (± 0.15)
n.d. *
14 4,4-dimethylergosta-8,24(28)-dien-3β-ol
0.7
0.08 (± 0.01)
0.9
0.17 (± 0.19)
1.1
0.21 (± 0.01)
0.7
0.15 (± 0.00)
0.3
0.03 (± 0.01)
0.3
0.05 (± 0.01)
0.6
0.06 (± 0.00)
total sterol content
100
11.22 (± 1.16)
100
20.17 (± 7.83)
100
19.64 (± 0.45)
100
21.39 (± 0.61)
100
9.26 (± 0.66)
100
14.09 (± 2.96)
100
9.78 (± 2.36)
Molecules 2018, 23, 1218 5 of 13
Ergosta-5,8,22-trien-3β-ol (lichesterol, 1) was detected in all of the six species tested. Among the
Mucormycetes, highest relative amounts of this intermediate were detected in Rhizopus spp.,
although these amounts were still lower than in A. fumigatus, which was included for comparison.
As expected, ergosta-5,7,22-trien-3β-ol (ergosterol, 2) was identified as the dominating sterol in all
the species studied. This is in agreement with a study that was carried out with R. arrhizus [39], in which
ergosterol was also identified as the sterol exhibiting highest abundance. This finding is supported
by a study that was investigating the phylogenetic distribution of fungal sterols [39]. One contrary
result was shown by Weete et al. [37], explaining that ergosta-7,22-dien-3β-ol (3) is the major sterol
(56.0 to 59.9%) and ergosterol (2) is only the second most abundant sterol (21.1–28.4%) in R. arrhizus.
Importantly, the relative content of ergosterol was highly variable between the species, ranging from
38.0% in Rh. pusillus to 76.3% in R. arrhizus. In A. fumigatus, the relative amount of ergosterol reached
95.0% of all the sterols in our experimental setup. This amount is slightly higher than what was shown
by a comprehensive study of Alcazar-Fuoli et al. [24], where A. fumigatus isolates reached relative
ergosterol amounts of 75.8 to 88.4%. Differences in experimental setup, like growth media and the age
of the cultures used for sterol extraction, might explain these differences.
Only minor amounts of ergosta-7,22-dien-3β-ol (3) were detected in most species. Only L. corymbifera
and Rh. pusillus showed little higher accumulation of 3, representing 3.5% and 1.9%, respectively,
whereas this intermediate was neither detected in M. circinelloides nor in A. fumigatus.
The relative amount of ergosta-5,7,22,24(28)-tetraen-3β-ol (4) and ergosta-7,22,24(28)-trien-3β-ol
(5) was very low in all of the samples (0.2–1.2%). This is in agreement with the value of 1.2% of 4
reported for M. rouxii [36].
Sterol 6, ergosta-5,7,24(28)-trien-3β-ol, was found in five out of the seven species tested
(A. fumigatus included), it exhibited the third highest abundancy among all the sterols in L. ramosa
(7.4%) and M. circinelloides (10.4%). Interestingly, sterol 6 was missing in L. corymbifera and Rh. pusillus.
In all Mucorales strains, significant amounts of ergosta-5,7-dien-3β-ol (7), the saturated side
chain analogue of ergosterol (2) were found (10.6–37.2%), making it the second most abundant
sterol after ergosterol in the Mucorales, whereas only a small amount (0.3%) of this sterol was
detected in A. fumigatus. Interestingly, in Rh. pusillus the relative amount of ergosterol (2) and
ergosta-5,7-dien-3β-ol (7) were nearly equal (38.0% and 37.2%), a characteristic that seems unique
for this species. McCorkindale et al. [34] also detected larger amounts of 7 in Mucorales (mean 45%;
n = 8) and also Weete et al. [39] identified 7 in Rhizomucor pusillus (formerly named Mucor pusillus).
This indicates a putative role of ergosta-5,7-dien-3β-ol (7) as a marker sterol for the identification
and classification of Mucorales species. This sterol was not found in studies evaluating sterols of
A. fumigatus [24,40], while we detected minor amounts (0.3%) in our cultures. From previous studies,
we learned that ergosta-5,7-dien-3β-ol (7) is only found in very little amounts in molds [25,41,42] and
yeasts [25,29,43,44].
Episterol, ergosta-7,24(28)-dien-3β-ol (8), was evident in all of the samples, ranging from 1.4%
(Rh. pusillus) to 2.4% in (L. corymbifera and R. microsporus). This sterol was also detected by Safe [36] in
another mucoralean fungus, M. rouxii, in which the amount of free and bounded 8 was shown to be
strongly dependent on the growth conditions (1.1–25.8%).
All of the Mucorales strains produced ergost-7-en-3β-ol (9) with maximum levels in L. corymbifera
(3.7%) and Rh. pusillus (3.0%). In contrast to the results of Weete et al. [37] (mean 13.5%; n = 6),
we detected clearly lower levels (0.3%) of 9 in R. arrhizus.
Low percentages (≤ 1.3%) of lanosterol (4,4,14-trimethylcholesta-8,24-dien-3β-ol, 10), T-MAS
(4,4-dimethylcholesta-8,24-dien-3β-ol, 11), and 4-methylergost-8-en-3β-ol (12) were ubiquitously found
in all of the samples.
Most interestingly, a high amount of eburicol (4,4,14-trimethylergosta-8,24(28)-dien-3β-ol, 13)
was detected to a degree that is usually only observed under azole treatment in fungi [25,29,41,43].
Levels reached up to 15.4% in Rh. pusillus, all other species also showed considerably high eburicol
levels, ranging from 2.0% (L. corymbifera) to 7.2% (M. circinelloides). In our experimental setup,
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we did not detect eburicol in A. fumigatus, which is in contrast to the sterol profile of A. fumigatus in
Alcazar-Fuoli et al. [24], where an eburicol content of approx. 1.9% was reported. Different growth
conditions and different growth media might explain this discrepancy.
The last detected sterol, 4,4-dimethylergosta-8,24(28)-dien-3β-ol (14), was present in all of the
samples, ranging from 0.3% (R. arrhizus) to 1.1% (M. circinelloides).
Sterol 1 and the sterols 4, 6, 10–14 were not explicitly mentioned in previous reports on the sterol
composition of Mucormycetes [26,34–39], but the percentages that we obtained in our study were in
the range of other fungi [22,24,40–42].
Additional to the relative amount of sterol intermediates, we also determined the actual amount
of each sterol, which was expressed as µg/mg biomass, (dry weight, Table 1). The total sterol content
was proportionately 1–2% of the total mycelial biomass, which is in agreement with what has been
detected for other Mucor species before [36]. Lowest amount of total sterols was found in R. arrhizus
(9.26 µg/mg) and highest in Rh. pusillus (21.39 µg/mg). The values of each intermediate determined
correlate with the relative amounts that were previously described. In A. fumigatus, a total sterol
content of 9.78 µg/mg was determined, of which 9.25 µg/mg was ergosterol, an amount that is
comparable to previously reported data [24].
2.2. Sterol Composition and Sterol Content of Posaconazole Treated R. arrhizus
To investigate the effect of the sterol C14-demethylase inhibitor POS on the sterol composition
and content of Mucorales, R. arrhizus hyphae confronted with sublethal concentrations (0.5 µg/mL) of
POS were compared to the sterol pattern of untreated hyphae Figures 2 and 3, Table 2. For comparison
and also to validate our results that were obtained with Mucorales, we included A. fumigatus, in which
the effect of azole treatment on sterol pattern has been extensively studied [24,25,40,41,45].
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Table 2. Sterol content and sterol composition of R. arrhizus and A. fumigatus confronted with sublethal concentrations of posaconazole (POS) when compared to the
untreated controls. Cultures were grown in RPMI1640 medium over night at 37 ◦C before being transferred to fresh media containing 0.5 µg/mL POS, or no POS.
Cultures were incubated for additional 4 h before sterol extraction. The results are presented as the average of two independent experiments, comprising six technical
replicates in total. Sterol composition is given as the relative amount of the respective sterol (%, in bold letters) of all sterols detected. Sterol content is expressed as
µg sterol intermediate/mg biomass (dry weight). Standard deviation is given in brackets.* n.d. = not detected, ** i.t. = in traces (< 0.04 µg/mg), major sterols are
indicated in red.
Compound
Relative [%] and Absolute [µg/mg] Amount of Sterols
R. arrhizus A. fumigatus
No. IUPACName Common Name POS Treated Untreated POS Treated Untreated
1 ergosta-5,8,22-trien-3β-ol Lichesterol
0.7
0.09 (± 0.01)
0.8
0.07(± 0.01)
1.2
0.10 (± 0.00)
1.2
0.12 (± 0.03)
2 ergosta-5,7,22-trien-3β-ol Ergosterol
58.5
7.52 (± 0.20)
76.3
7.07(SD ± 0.04)
84.1
7.41 (± 1.05)
95.0
9.29 (± 2.28)
3 ergosta-7,22-dien-3β-ol
0.1
0.01 (± 0.01)
0.2
0.02 (± 0.01)
0.1
0.01 (± 0.01)
n.d. *
4 ergosta-5,7,22,24(28)-tetraen-3β-ol
0.7
0.09 (± 0.02)
1.0
0.09 (± 0.02)
0.8
0.07 (± 0.01)
0.7
0.06 (± 0.01)
5 ergosta-7,22,24(28)-trien-3β-ol
0.1
0.01 (± 0.00)
0.2
0.03 (± 0.02)
0.2
0.01 (± 0.01)
0.2
0.02 (± 0.00)
6 ergosta-5,7,24(28)-trien-3β-ol
0.9
0.12 (± 0.12)
2.6
0.24 (± 0.22)
0.6
0.05 (± 0.04)
0.6
0.06 (± 0.01)
7 ergosta-5,7-dien-3β-ol
5.1
0.66 (± 0.33)
10.6
0.98 (± 0.19)
1.9
0.17 (± 0.10)
0.3
0.03 (± 0.00)
8 ergosta-7,24(28)-dien-3β-ol Episterol
0.8
0.10 (± 0.00)
2.1
0.20 (± 0.13)
1.0
0.09 (± 0.02)
0.8
0.08 (± 0.01)
9 ergost-7-en-3β-ol
0.1
0.01(± 0.01)
0.3
0.03 (± 0.02)
i.t. ** n.d. *
10 4,4,14-trimethylcholesta-8,24-dien-3β-ol Lanosterol
2.5
0.33 (± 0.26)
0.7
0.07 (± 0.03)
1.3
0.12 (± 0.12)
0.2
0.02 (± 0.00)
Molecules 2018, 23, 1218 8 of 13
Table 2. Cont.
Compound
Relative [%] and Absolute [µg/mg] Amount of Sterols
R. arrhizus A. fumigatus
No. IUPACName Common Name POS Treated Untreated POS Treated Untreated
11 4,4-dimethylcholesta-8,24-dien-3β-ol T-MAS i.t. **
0.2
0.02 (± 0.00)
0.4
0.04 (± 0.00)
0.4
0.04 (± 0.00)
12 4-methylergost-8-en-3β-ol
0.1
0.01(± 0.01)
0.2
0.02 (± 0.02)
n.d. * n.d. *
13 4,4,14-trimethylergosta-8,24(28)-dien-3β-ol Eburicol
29.1
3.74 (± 1.58)
3.7
0.34 (± 0.12)
6.9
0.61 (± 0.80)
n.d.*
14 4,4-dimethylergosta-8,24(28)-dien-3β-ol i.t. **
0.3
0.03 (± 0.01)
0.7
0.06 (± 0.02)
0.6
0.06 (SD ± 0.00)
15 14-methylergosta-8,24(28)-diene-3β,6α-diol
0.7
0.09 (± 0.11)
n.d. * n.d. * n.d.*
total sterol content
100
12.86 (± 1.30)
100
9.26 (± 0.66)
100
8.81 (± 0.08)
100
9.78 (± 2.36)
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As expected, the relative amount of ergosterol (2) was significantly reduced by 17.8% in R. arrhizus
due to POS treatment. On the other hand, eburicol (13), which is one of the substrates of the azoles’
target enzyme C14-demethylase, increased by 25.4% (Figure 3), which underlines the enzyme inhibiting
properties of POS also in R. arrhizus and it further indicates that 13 is the favored substrate for sterol
C14-demethylase in Mucorales (Figure 4).
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Figure 4. Putative alternative sterol biosynthesis pathway from lanosterol in Mucorales in the presence
of posaconazole. Enzymes: (A) sterol C14-demethylase, (B) sterol C24-methyltransferase, (C) sterol
C4-demethylase complex, (D) sterol C5-desturase.
Surprisingly, the ctual amount of ergosterol (2) relative to the biomass significantly ncreased in
POS tre ted R. arrhizu hyphae (from 7.07 µg/mg to 7.5 µg/mg). Furthermore, a significan increase
of the total sterol content (from 9.26 µg/mg to 12.86 µg/mg) was evident, which is most likely due to
the accumulation of new sterols and the increased amount of ergosterol precursors, such as eburicol,
which is increased eight-fold when compared to the untreated samples. This finding reflects what
was shown by Weete and Wise [26] in propiconazole treated M. rouxii. However, this is contrary to
our observations in A. fumigatus, where inhibition of sterol C14-demethylase resulted in ergosterol
reduction (from 9.29 µg/mg to 7.41 µg/mg), and in this course resulted in a decrease of the total sterol
content from 9.78 µg/mg to 8.81 µg/mg, although this decrease was not significant. Our results that
were obtained for A. fumigatus correlate with the results of Alcazar-Fuoli et al. [27], showing that in
strains with defective sterol C14-demethylase, caused by mutations in one of the two cyp51 genes,
statistically lower amounts of total ergosterol were detected than in the wildtype strain.
Another sterol, ergosta-5,7-dien-3β-ol (7), was clearly reduced from 10.6% to 5.1% in R. arrhizus.
In A. fumigatus, the opposite effect was observed for 7, resulting in a slight increase from 0.3% to 1.9%.
Ergosta-5,7-dien-3β-ol (7) is a substr te for sterol C22-des turase [25], the final enzyme in ergosterol
biosynt e is, which converts 7 into ergost rol (2). The decreas f non-C14-methylated sterol levels
under azole tr atment ca e expl ined by an up-re ulation of ergosterol biosynthesis enzymes,
which is aimed at converting all of the intermediates into ergosterol (e.g., 7), to avoid the impairment
of membrane function. In both, R. arrhizus and A. fumigatus, a significant accumulation (relative and
total amount) of lanosterol (10, Figures 1–4) was observed. Lanosterol (10) is a further physiological
substrate for the inhibited enzyme sterol C14-demethylase (Figures 1 and 4), which explains the
accumulation due to enzyme inhibition, even though eburciol (13) was shown to be the favored
enzyme substrate in molds (Mucorales and A. fumigatus) [24–27].
Most interestingly, the non-physiological 14-methylergosta-8,24(28)-diene-3β,6α-diol (15) was
found (0.7%) in POS that was treated R. arrhizus. Accumulation of this toxic intermediate [28,29,46]
under the inhibition of sterol C14-demethylase was only detected in yeasts so far, but not in A. fumigatus
or another filamentous fungus (Figure 4). Further studies are needed to verify if the accumulation of
14-methylergosta-8,24(28)-diene-3β,6α-diol (15) is unique for R. arrhizus or is ubiquitously found in
clinically relevant Mucorales upon azole treatment.
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The relative amounts of sterols 1, 3–6, 8, 9, 11, 12, 14 were not, or only to a minor extent, affected
by POS treatment Table 2.
In conclusion, the azole activity in Mucorales results in significant alterations of the sterol
composition, but it does not subsequently lead to a reduction of the total sterol content. The high
amount of eburicol, even in untreated hyphae of the Mucorales, let us hypothesize that these fungi
could be less affected by the accumulation of non-physiological intermediates due to azole treatment,
which is reflected in their lower sensitivity to azole drugs when compared to other molds. In the
genome of R. arrhizus two paralogous genes encoding for sterol C14-demethylase have been found [20].
It remains to be elucidated if the expression of both the genes is effected to a similar extent in the
presence of azoles. So far, our results in R. arrhizus let us hypothesize that sterol C14-demethylase
is only partly inhibited, as R. arrhizus is still able to synthesize ergosterol. This has been shown for
other fungi as well, and it reflects that molds inherit a wide repertoire of adaption mechanisms to
overcome such drawbacks. From the sterol pattern, we learn that in Mucorales the entry into the
post-lanosterol pathway of ergosterol biosynthesis is similar to other molds, whereas under azole
treatment, differences to molds, e.g., A. fumigatus were detected, resulting in the accumulation of
a non-physiological sterol (14-methylergosta-8,24(28)-diene-3β,6α-diol, 15) which has so far only
been found in azole treated yeasts (Figure 4). Because the Mucorales exhibit high variability in their
susceptibility to azoles, it is of special interest to decipher the effect of azoles on sterol composition
and the content of other clinically relevant mucoralean fungi.
3. Material and Methods
3.1. Fungal Strains Used in This Study
The following fungal strains, all being obtained from the strain collection of the Division of
Hygiene and Medical Microbiology, Medical University Innsbruck (Innsbruck, Austria), were used
for sterol analysis: Aspergillus fumigatus (ATCC46645), Lichtheimia corymbifera (CBS 109940),
Lichtheimia ramosa (CBS 101.55), Mucor circinelloides (CBS 394.68), Rhizomucor pusillus (CBS 219.31),
Rhizopus arrhizus (CBS 126971), and Rhizopus microsporus (CBS 102277).
3.2. Fungal Growth and Culture Conditions
All of the strains were cultivated on supplemented minimal agar (SUP) at 37 ◦C until sporulation
(five days). Spores were obtained by harvesting them with sterile spore suspension buffer (0.9% NaCl,
0.01% Tween80). To obtain mycelia for sterol extraction, all of the strains were cultivated in RPMI1640
cell culture medium (Sigmaaldrich, Vienna, Austria) at 37 ◦C with shaking overnight. Cultures of
R. arrhizus and R. microsporus with optimal growth (fine mycelia, no formation of hyphal pellets) were
harvested and transferred to a new shake flask containing RPMI1640 plus 0.5 µg/mL posaconazole
(POS). Cultures were further incubated in the presence of posaconazole for 4 h. Untreated controls
were transferred into new medium without posaconazole. Then, the cultures were harvested by
filtration, washed, and freeze dried to determine the fungal biomass on dry weight basis.
3.3. Sterol Extraction
Six mg of dry fungal biomass were used for sterol extraction as described by Müller et al. [25].
3.4. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis of Sterol TMS Ethers
Sterol pattern was determined by GC-MS, according to Müller et al. [25,43]. The quantification,
managed with an external calibration with ergosterol, consists of six levels with concentrations up to
20 µg/mg. The base peak of each sterol TMS ether were taken as a quantifier ion for calculating the peak
areas for IS cholestanem/z 217, 1 ergosta-5,8,22-trien-3β-ol (lichesterol)m/z 363, 2 ergosta-5,7,22-trien-3β-ol
(ergosterol) m/z 363, 3 ergosta-7,22-dien-3β-ol m/z 343, 4 ergosta-5,8,22,24(28)-tetraen-3β-ol m/z 466,
5 ergosta-7,22,24(28)-trien-3β-ol m/z 343, 6 ergosta-5,7,24(28)-trien-3β-ol m/z 363, 7 ergosta-5,7-dien-3β-ol
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m/z 365, 8 ergosta-7,24(28)-dien-3β-ol (episterol) m/z 343, 9 ergost-7-en-3β-ol m/z 472,
10 4,4,14-trimethylcholesta-8,24-dien-3β-ol (lanosterol) m/z 393, 11 4,4-dimethylcholesta-8,24-dien-3β-ol
(T-MAS) m/z 379, 12 4-methylergost-8-en-3β-ol m/z 486, 13 4,4,14-trimethylergosta-8,24(28)-dien-3β-ol
(eburicol) m/z 407, 14 4,4-dimethylergosta-8,24(28)-dien-3β-ol m/z 408, and 15 14-methylergosta-
8,24(28)-diene-3β,6α-diol m/z 377. Sterols 4,4-dimethylcholesta-8,14,24-trien-3β-ol (FF-MAS)
4,4-dimethylergosta-8,14,24(28)-trien-3β-ol, and 14-methylergosta-8,24(28)-dien-3β-ol were not
detected in this study. For detailed information about these sterols, see literature [25]. Representative
selected ion chromatograms of sterol fractions from R. arrhizus are given in Figure 2.
The amount of each sterol was expressed as µg per mg dry weight. The results represent the mean
(µg/mg± S.D.) of two independent biological replicates, including six technical parallels. Experiments
involving POS treatment were carried out in triplicate. The sterol composition is expressed as relative
amount of total sterols (%).
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